New IgE antibody trial targets Hard-to-Treat cancers

NCT ID NCT06547840

First seen Apr 18, 2026 · Last updated Apr 28, 2026 · Updated 2 times

Summary

This early-phase trial tests a new drug called MOv18 IgE in people with advanced ovarian, endometrial, or triple-negative breast cancers that have a specific marker (folate receptor alpha). The study has two parts: first, finding a safe dose, and then checking how well the drug works. About 45 participants will be enrolled to see if the drug can shrink tumors or slow disease progression.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Bristol Haematology and Oncology Centre

    RECRUITING

    Bristol, BS2 8ED, United Kingdom

  • Cambridge University - Addenbrooke's Hospital

    RECRUITING

    London, CB2 0QQ, United Kingdom

  • Edinburgh Cancer Research Centre

    RECRUITING

    Edinburgh, EH4 2XR, United Kingdom

  • Guy's Hospital

    RECRUITING

    London, SE1 3SS, United Kingdom

  • Leeds Teaching Hospitals NHS Trust

    RECRUITING

    Leeds, LS9 7LP, United Kingdom

  • University College London Hospital

    RECRUITING

    London, NW1 2BU, United Kingdom

  • University Hospital Southampton NHS Foundation Trust

    RECRUITING

    Southampton, SO16 6HU, United Kingdom

Conditions

Explore the condition pages connected to this study.